CytomX Therapeutics Inc (NASDAQ: CTMX) is 32.90% higher on its value in year-to-date trading and has touched a low of $1.04 and a high of $2.86 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CTMX stock was last observed hovering at around $2.10 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $2.06, the stock is -1.62% and 15.71% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing -1.90% at the moment leaves the stock 33.04% off its SMA200. CTMX registered -2.37% loss for a year compared to 6-month gain of 49.28%. The firm has a 50-day simple moving average (SMA 50) of -$0.21 and a 200-day simple moving average (SMA200) of $4.88.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 46.10% loss in the last 1 month and extending the period to 3 months gives it a 46.10%, and is -19.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.32% over the week and 10.82% over the month.
CytomX Therapeutics Inc (CTMX) has around 122 employees, a market worth around $139.50M and $101.21M in sales. Profit margin for the company is -0.56%. Distance from 52-week low is 98.08% and -27.85% from its 52-week high.
CytomX Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.05 with sales reaching $20.6M over the same period.The EPS is expected to shrink by -3780.00% this year, but quarterly earnings will post -19.30% year-over-year. Quarterly sales are estimated to shrink -12.30% in year-over-year returns.
82 institutions hold shares in CytomX Therapeutics Inc (CTMX), with institutional investors hold 49.33% of the company’s shares. The shares outstanding are 67.31M, and float is at 66.47M with Short Float at 2.46%. Institutions hold 48.64% of the Float.
The top institutional shareholder in the company is Tang Capital Management, LLC with over 6.6 million shares valued at $11.35 million. The investor’s holdings represent 9.89% of the CTMX Shares outstanding. As of Jun 29, 2023, the second largest holder is BVF Inc. with 6.6 million shares valued at $11.34 million to account for 9.88% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 4.9 million shares representing 7.34% and valued at over $8.43 million, while Acadian Asset Management. LLC holds 3.97% of the shares totaling 2.65 million with a market value of $4.56 million.
CytomX Therapeutics Inc (CTMX) Insider Activity
The most recent transaction is an insider sale by McCarthy Sean A., the company’s CEO. SEC filings show that McCarthy Sean A. sold 13,551 shares of the company’s common stock on Dec 20 ’23 at a price of $1.38 per share for a total of $18710.0. Following the sale, the insider now owns 0.45 million shares.
CytomX Therapeutics Inc disclosed in a document filed with the SEC on Dec 20 ’23 that ROWLAND LLOYD A (General Counsel) sold a total of 4,077 shares of the company’s common stock. The trade occurred on Dec 20 ’23 and was made at $1.38 per share for $5629.0. Following the transaction, the insider now directly holds 97996.0 shares of the CTMX stock.
Still, SEC filings show that on Dec 20 ’23, BELVIN MARCIA (SVP, Chief Scientific Officer) disposed off 4,077 shares at an average price of $1.38 for $5628.0. The insider now directly holds 155,124 shares of CytomX Therapeutics Inc (CTMX).
